| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H12O4 |
| Molecular Weight | 196.1999 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(C=O)=CC(OC)=C1OC
InChI
InChIKey=OPHQOIGEOHXOGX-UHFFFAOYSA-N
InChI=1S/C10H12O4/c1-12-8-4-7(6-11)5-9(13-2)10(8)14-3/h4-6H,1-3H3
| Molecular Formula | C10H12O4 |
| Molecular Weight | 196.1999 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
3,4,5-Trimethoxybenzaldehyde is a key intermediate in the synthesis of trimethoprim[2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine], which, in addition to its antibacterial activity, possesses the property of significantly strengthening the bactericidal activity of sulfanilamide preparations. Also, 3,4,5-Trimethoxybenzaldehyde id used for the synthesis of Isoamoenylin, which showed moderate antioxidative and weak antibacterial activities. An A-ring analogue of colchicine, 3,4,5-trimethoxybenzaldehyde, can stop the antimitotic drug IKP104-induced unfolding of tubulin significantly. 3,4,5-trimethoxybenzaldehyde stimulated tubulin-dependent GTP hydrolysis.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 2.5 mM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|